T. Wagener

691 total citations
12 papers, 496 citations indexed

About

T. Wagener is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, T. Wagener has authored 12 papers receiving a total of 496 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 5 papers in Surgery. Recurrent topics in T. Wagener's work include Sarcoma Diagnosis and Treatment (6 papers), Vascular Tumors and Angiosarcomas (3 papers) and Testicular diseases and treatments (2 papers). T. Wagener is often cited by papers focused on Sarcoma Diagnosis and Treatment (6 papers), Vascular Tumors and Angiosarcomas (3 papers) and Testicular diseases and treatments (2 papers). T. Wagener collaborates with scholars based in Netherlands, Belgium and United Kingdom. T. Wagener's co-authors include J. Buesa, William P. Steward, Jacques Rouëssé, Armando Santoro, V. Bramwell, W. Ruka, M Burgers, Julio C Priario, Richard Sylvester and Özlem Anak and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

T. Wagener

11 papers receiving 475 citations

Peers

T. Wagener
Thomas A. Sheldon United States
Ann Hanly Ireland
W. Rhomberg Austria
Dirk Elling Germany
Bahriye Payzın Türkiye
Akshara Richhariya United States
Juan Diego Morillas Spain
Kenneth Kyle United States
Mariella Sorarů Italy
C.A. Lawton United States
Thomas A. Sheldon United States
T. Wagener
Citations per year, relative to T. Wagener T. Wagener (= 1×) peers Thomas A. Sheldon

Countries citing papers authored by T. Wagener

Since Specialization
Citations

This map shows the geographic impact of T. Wagener's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Wagener with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Wagener more than expected).

Fields of papers citing papers by T. Wagener

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. Wagener. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Wagener. The network helps show where T. Wagener may publish in the future.

Co-authorship network of co-authors of T. Wagener

This figure shows the co-authorship network connecting the top 25 collaborators of T. Wagener. A scholar is included among the top collaborators of T. Wagener based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. Wagener. T. Wagener is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Ducreux, Michel, Eric Van Cutsem, Jean‐Luc Van Laethem, et al.. (2005). A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. European Journal of Cancer. 41(3). 398–403. 96 indexed citations
2.
Brunkhorst, R., J. Bommer, Jonathan Braun, et al.. (2004). Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Nephrology Dialysis Transplantation. 19(5). 1224–1230. 59 indexed citations
3.
4.
5.
6.
Catimel, G., Jaco J. Verweij, T. Wagener, et al.. (1993). A phase II study of taxotere in patients with advanced head and neck cancer. European Journal of Cancer. 29. S139–S139. 4 indexed citations
7.
Buesa, J., H.T. Mouridsen, A.T. van Oosterom, et al.. (1991). High-dose DTIC in advanced soft-tissue sarcomas in the adult. Annals of Oncology. 2(4). 307–309. 85 indexed citations
8.
Blackledge, G., A. van Oosterom, Henning T. Mouridsen, et al.. (1989). The place of chemotherapy in the management of soft tissue sarcoma: Experiences of the EORTC soft tissue and bone sarcoma group. Clinical Oncology. 1(2). 106–109. 4 indexed citations
9.
Bramwell, Vivien, Armando Santoro, Jacques Rouëssé, et al.. (1988). Review of the clinical trials activity of the soft tissue and bone sarcoma group of the european organization for research and treatment of cancer. Seminars in Surgical Oncology. 4(1). 45–52. 4 indexed citations
10.
Gasparini, Marco, Jacques Rouëssé, T. Wagener, et al.. (1985). Phase II study of cisplatin in advanced osteogenic sarcoma. European Organization for Research on Treatment of Cancer Soft Tissue and Bone Sarcoma Group.. PubMed. 69(2). 211–3. 18 indexed citations
11.
Buesa, J., Henning T. Mouridsen, Armando Santoro, et al.. (1984). Treatment of advanced soft tissue sarcomas with low-dose methotrexate: a phase II trial by the European Organization of Research on Treatment for Cancer (EORTC) Soft Tissue and Bone Sarcoma Group.. PubMed. 68(4). 683–4. 5 indexed citations
12.
Pauw, Ben de, T. Wagener, H. Wessels, & C. Haanen. (1980). Spontaneous DNA synthesis by subpopulations of lymphocytes in Hodgkin's disease. European Journal of Cancer (1965). 16(10). 1329–1332.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas A. Sheldon Breakdown of academic impact, for papers by Ann Hanly Breakdown of academic impact, for papers by W. Rhomberg Breakdown of academic impact, for papers by Dirk Elling Breakdown of academic impact, for papers by Bahriye Payzın Breakdown of academic impact, for papers by Akshara Richhariya Breakdown of academic impact, for papers by Juan Diego Morillas Breakdown of academic impact, for papers by Kenneth Kyle Breakdown of academic impact, for papers by Mariella Sorarů Breakdown of academic impact, for papers by C.A. Lawton
Rankless by CCL
2026